Monday, April 23, 2018
News
NEWS HOME
»
PRESS RELEASES

AHF: 'Shameless' Gilead Hikes Key AIDS Drug Pricing 6.9% Despite Recent Patent Expiration
  SocialTwist Tell-a-Friend  
   


Date: 11-01-2018 12:48PM
Source: AIDS Healthcare Foundation
Category: General, Consumer Interest, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Los Angeles, United States

Business Wire India

AIDS Healthcare Foundation (AHF), the largest global AIDS organization and a vocal critic of runaway drug pricing and drug profiteering, today blasted Gilead Sciences, Inc. over newly instituted price hikes of 6.9% on three key HIV/AIDS treatments despite the fact that the patent for a key component of each treatment—tenofovir—expired in mid-December.

AHF branded Gilead’s latest pricing action a shameless move by what one expert called “perhaps the most ethically challenged drug company,” in the drug pricing documentary, “Your Money or Your Life.”

In October 2017, as patent expiration loomed for Gilead, AHF called on Gilead to reduce the price of its tenofovir-based drug regimens—including Truvada—by as much as 90%.

The California drug company has made billions off of sales of its tenofovir-based drugs since the FDA first approved Gilead’s tenofovir disoproxil fumarate (TDF), branded as Viread, on October 26, 2001. That patent expired on December 15, 2017, with the patent on a pediatric version of the drug set to expire in early 2018. All the while Gilead simultaneously sought to ‘evergreen’ and manipulate the patent extension process.

“It is nothing short of grotesque that Gilead raised the price of Truvada by 6.9% despite the fact that it is now off patent and generic,” said Michael Weinstein, President of AIDS Healthcare Foundation. “This is a lifesaving HIV/AIDS treatment that they have already made billions off of and they are now trying to squeeze the well dry. Also, if Gilead is truly committed to providing and enhancing access to Truvada for use as pre-exposure prophylaxis or PrEP to prevent HIV acquisition by uninfected individuals, it is unconscionable for them to also charge this steep price on a now generic medicine. We call on other AIDS and community groups nationwide to join us in calling on Gilead to reduce its pricing, and also loudly renew our October call on Gilead to reduce the price of its tenofovir-based drug regimens—including Truvada—by 90% as well as on other combination therapies using tenofovir that Gilead makes in partnership with companies like BMS and Janssen.”

Since FDA approval of the drug in 2001, the TDF formulation of tenofovir has become a cornerstone of other big money Gilead combination HIV/AIDS treatment therapies beyond Viread, including:

  • Atripla (efavirenz + tenofovir disoproxil fumarate + emtricitabine—made in partnership with Bristol-Myers Squibb);
  • Complera (rilpivirine + tenofovir disoproxil fumarate + emtricitabine—made in partnership with Janssen Theraputics);
  • Stribild, the four-drug-in-one tablet (elvitegravir + cobicistat + tenofovir disoproxil fumarate + emtricitabine);
  • Truvada (tenofovir disoproxil fumarate + emtricitabine), Gilead’s blockbuster HIV/AIDS treatment that is also the medication component used for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition; and
  • Viread (tenofovir disoproxil fumarate or ‘TDF’ - previously cited above.

In February 2016, AHF filed a lawsuit against Gilead over its manipulation of the patent system in order to derail competition to its HIV medicines. As reported at the time by Ed Silverman on the health news service, STAT, “At issue is tenofovir, or TDF, which is a cornerstone of the combination HIV treatments that Gilead sells. The patent on the TDF compound expires in December 2017 and Gilead hopes to replace it with a modified version known as TAF. The patent on TAF doesn’t expire until May 2022, and the prospect of nearly five more years of sales without generic competition is extremely valuable.”

He also noted, “There is another important difference between the two compounds — TAF is more potent and causes fewer side effects, notably bone damage and kidney toxicity.”

In 2014, in anticipation of Viread’s upcoming patent expiration, Gilead pulled a much more efficacious 30mg lower dose version of Viread off its development shelf and instead began the evergreening process by filing its first New Drug Application (NDA) for the modified Viread molecule, tenofovir alafenamide, or TAF (later branded Vemlidy).

It should be noted that Teva, an Israeli multinational pharmaceutical company and generic drug manufacturer, is allowed to begin production of a generic version of Viread as of December 15, 2017, resulting from its litigation against Gilead. Truvada, which contains the older version of Viread combined with a second Gilead drug called Emtriva, can also go generic as of December 2017.

What is most telling about Gilead’s corporate conscience—or lack thereof—is that after many years of incredible successes, this newer TAF version of Viread, which has a significantly better adverse event profile (particularly regarding renal side effects that impact African Americans much more) was reportedly left on the shelf post-development by Gilead Sciences for years. The reason for doing so is obvious: to maximize profits via the evergreening process by waiting until just the right time to begin filing new drug applications for all previously approved combination therapies. This effectively extends patent life of Gilead’s drug portfolio and greatly enhances the profit margins for Gilead.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to more than 855,000 individuals in 39 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare.



CONTACTS :

AIDS Healthcare Foundation
Ged Kenslea
Senior Director, Communications
Telephone: (323) 308-1833
Mobile: (323) 791-5526
gedk@aidshealth.org

More Press Releases

EMQ Partners with Leading Vietnam Bank to Boost Remittance Capabilities across Southeast Asia

STATS Names Ryan Paterson Chief Global Officer

Oath Hires Former Alibaba Group Executive as President & COO

Over 600 World Leaders To Gather At Horasis Global Meeting 2018 To Share Insights & Innovations On How To Jointly Inspire Our Future

J.P. Morgan Collaborates with BlackRock to Launch New ESG Suite of Indices: The J.P. Morgan ESG Index (JESG)

Beko Attends EuroCucina 2018 With Celebrity Chef Lisa Faulkner Whilst Cooking up a Fantastic Feast with Renowned Italian Chef Alessandro Borghese

FLIR Systems Completes Strategic Investment in DroneSense

Adani Foundation Inaugurates Project Utthan

Merck Foundation and Tata Memorial Centre Signs MoU to Build Cancer Care Capacity in Africa

Prism Cement Limited Is Now Prism Johnson Limited

First Year’s Service for Smallest Rolls-Royce

Young Indian CA Firms Go International

Tata Starbucks Launches Limited-Edition Beverage, Celebration 150, in Stores to Commemorate 150 Years of the Tata Group

AGCO Power Celebrates its 75th Anniversary

Leading Classic Hardware Emulation Provider, Stromasys, Leverages Expertise to Enhance Support Options for OpenVMS Clients

Beko Showcases Its Latest Design and Product Innovations in Milan at EuroCucina

Customer Satisfaction Should Be Top Priority in the Real Estate Industry: Gaurav Gupta

Great Success for the GIFAS Mission to Strengthen French-Indian Aerospace Cooperation and Support the Make in India Policy

Twist Bioscience Accelerates Global Expansion with Strategic Asia Pacific Distribution Agreements

RAS AL KHAIMAH (RAK) Ruler Delivers Keynote Opening Speech to 14th Arabian Hotel Investment Conference

IDEMIA and JCB Trial of the First F.CODE Payment Card in Japan

Mumbai's Biggest SummerFest at Avenue 54, Santacruz

New Strategies in Building BoP Ecosystem

Clientron to Display Its Latest POS Terminals at Food & Hotel Asia 2018 Expo

P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany

ABB: Profitable Growth

Red Bull Can You Make It? Teams Make It to the Finish Line in Amsterdam

Forevermark Launches the Traditional Setting Collection

Snapdeal Announces Mega Deals Festival; Offers Upto 70 Percent Discount

Delighting Home Buyers for Decades - DSR Infra

Aaseya Announces Partnership With Pegasystems

E-Global Trade & Finance Group Inc. Better-Known as Forex4you Wins the Le Fonti Awards in Hong Kong in the Forex Investment Business

Phonup Offers One-Year Warranty on Pre-Owned Phones

Pfizer Lease Signed; USD 1.8B Construction Loan From Blackstone Secured; CanAm Set to Close on Initial Round of EB-5 Funds Raised for Tishman Speyer’s Spiral Project

Loomis Sayles Appoints New Director of ESG (Environmental, Social and Governance)

Corona Corporation Switches to Rimini Street for Oracle EBS Support

 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
UP police nabbed four wanted criminals a...
BJP delegation meets Suresh Prabhu, dema...
30-yr-old man held for sexually assaulti...
Kerala to send body of Latvian woman to ...
Keys sends U.S. into second straight Fed...
Record number of Muslims to go for haj 2...
More...    
 
 Top Stories
UP police nabbed four wanted crimin... 
Mexican president says optimistic a... 
Kerala to send body of Latvian woma... 
Keys sends U.S. into second straigh... 
30-yr-old man held for sexually ass... 
BJP delegation meets Suresh Prabhu,... 
Mahesh Babu's 'Bharath Ane Nenu' to... 
Decision to drop Fawad Alam unanimo...